Carfilzomib Gets Preliminary Thumbs Up
Onyx Pharmaceuticals's carfilzomib cancer drug received an 11-to-1 favorable vote from a Food & Drug Administration advisory panel. A final decision is expected by the end of next month, and ONXX is surging 38 percent before the bell on my tradeMONSTER platform.
Bed Bath Sees Cost Squeeze
Bed Bath & Beyond reported better-than-expected earnings and revenue. But management expects costs to rise as it battles Amazon.com. Second-quarter earnings are expected to be just $0.97 to $1.03 per share, below the $1.08 consensus estimate. BBBY drops 10 percent in the premarket.
Clarcor Earnings, Revenue Miss
Clarcor reported second-quarter earnings of $0.65 on revenues of $284.9 million. Estimates were for $0.70 and $305.7 million respectively. Guidance was also weak. CLC falls more than 6 percent on my tradeMONSTER platform.
Red Hat Falls on Weak Guidance
Red Hat's earnings beat, but earnings in the current quarter are expected to be $0.28 to $0.29 a share, and revenue will be no more than $322 million. Analysts expected $0.29 and $330.8 million, respectively. RHT is down 10 percent in the pre.
More From optionMONSTER
